Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px
Document › Details

Stratec Biomedical AG. (6/18/14). "Press Release: Stratec Annual General Meeting. Shareholders Elect New Supervisory Board and Approve Ddividend Increase". Birkenfeld.

Organisation Organisation Stratec Biomedical AG (Frankfurt: SBS, Prime Standard, TecDAX)
  Group Stratec (Group)
Product Product contract manufacturing (laboratory equipment and instruments)
Person Person Loy, André (Stratec 201107 Investor Relations)

At today's Annual General Meeting in Pforzheim, the shareholders of STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) approved all of the agenda items put to the vote with large majorities in each case.

Prof. Dr. Stefanie Remmele, Landshut, Professor for medical engineering at the Hochschule Landshut - University of Applied Sciences, was newly elected to the three-member Supervisory Board and thus succeeds Prof. Dr. Hugo Hämmerle. The previous Supervisory Board Chairman, Fred K. Brückner, and the previous Deputy Supervisory Board Chairman, Wolfgang Wehmeyer, stood for re-election and were once again elected to the supervisory body by the Annual General Meeting.

At the subsequent constitutive meeting of the Supervisory Board, Fred K. Brückner was once again elected as Chairman. Wolfgang Wehmeyer was re-elected as Deputy Supervisory Board Chairman and as the independent financial expert pursuant to § 100 (5) of the German Stock Corporation Act (AktG).

STRATEC is distributing a dividend of € 0.60 per share to its shareholders for the 2013 financial year (previous year: € 0.56). The distribution total amounts to € 7.1 million and will be paid to shareholders via their depository banks from June 20, 2014. The dividend has thus been increased for the tenth year in succession since the initiation of dividend payments in 2004.

Further information about the Annual General Meeting can be found on the company's website at


STRATEC Biomedical AG ( designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. The company develops its products on the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the TecDAX select index of the German Stock Exchange.

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Partnering Opens 600x60px

More documents for Stratec (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top